CK
CASC

Carnick & Kubik’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Carnick & Kubik’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-25
Closed -$411 – 382
2015
Q3 		$411 Buy
+25
New +$513 ﹤0.01% 404

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Carnick & Kubik's CASC Position: Q4 2015 in Review

Carnick & Kubik sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 25 shares — an estimated $411 sold.

Carnick & Kubik first reported a position in CASC in Q3 2015 and held it in 1 quarter. The position peaked at $411 in Q3 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

  • Carnick & Kubik reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Carnick & Kubik sold 25 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $411.
  • Carnick & Kubik first reported a position in Cascadian Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Carnick & Kubik's Cascadian Therapeutics, Inc. position peaked at $411 in Q3 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Carnick & Kubik's 13F filing for Q4 2015, filed 11 Feb 2016.